FDA
-
-
-
-
-
-
-
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
-
-
-
-
-
-
-
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
-
-
-
-
-
-
-
After-Hours Stock Movers 06/08: (LYRA) (FSR) (LMNR) Higher; (ONDS) (CMTL) (PATH) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Movers 06/17: (WATT) (INWK) (GRPN) Higher; (CEMI) (ATNM) (NCLH) Lower (more...)
-
-
-
-
-
-
-
Aclaris Therapeutics (ACRS) Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing ANDA for Generic Version of RHOFADE cream, 1%
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oasmia Pharmaceutical, Aclaris Therapeutics, Evolent Health, and International Flavors & Fragrances and
-
-
-
-
-
-
-
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
-
328,282 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

